EGFR
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR signaling drives many cellular responses.
EGFR Inhibitors |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 5318 | AEE 788 |
| Potent EGFR and VEGFR inhibitor | |
| 6812 | Afatinib dimaleate |
| Potent dual specificity EGFR/HER2 inhibitor; active in vivo | |
| 1276 | AG 1478 hydrochloride |
| Highly potent EGFR-kinase inhibitor | |
| 0414 | AG 490 |
| EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor | |
| 1555 | AG 825 |
| Selective ErbB2 inhibitor | |
| 5916 | Canertinib dihydrochloride |
| Potent EGFR kinase inhibitor | |
| 6231 | Dacomitinib |
| Potent irreversible pan ErbB inhibitor | |
| 7424 | EMI 48 |
| Inhibitor of EGFR mutants | |
| 7194 | Erlotinib Hydrochloride |
| Potent, reversible EGFR tyrosine kinase inhibitor | |
| 1110 | Genistein |
| EGFR kinase inhibitor. Also estrogen and PPARγ ligand | |
| 2239 | GW 583340 dihydrochloride |
| Potent dual EGFR/ErbB2 inhibitor; orally active | |
| 6813 | Ibrutinib |
| Potent ErbB4 inhibitor; also inhibits BTK | |
| 3000 | Iressa |
| Orally active, selective EGFR inhibitor | |
| 6962 | JBJ-03-142-02 |
| Highly potent EGFR and ErbB2 inhibitor; inhibts wild type and mutated receptors | |
| 3352 | JNJ 28871063 hydrochloride |
| Potent ErbB receptor family inhibitor | |
| 6811 | Lapatinib |
| Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor | |
| 7371 | Neratinib |
| Potent HER2 receptor tyrosine kinase and EGFR kinase inhibitor | |
| 2615 | PD 158780 |
| Potent ErbB receptor family inhibitor | |
| 6349 | Pelitinib |
| Potent and irreversible EGFR inhibitor; orally bioavailable | |
| 4941 | PKI 166 hydrochloride |
| Potent EGFR-kinase inhibitor | |
| 2794 | PP 3 |
| EGFR-kinase inhibitor. Also Src kinase negative control | |
| 3599 | TAK 165 |
| Potent and selective ErbB2 inhibitor | |
| 7640 | Tucatinib |
| Potent and selective ErbB2 inhibitor | |
| 3115 | WHI-P 154 |
| Potent EGFR inhibitor. Also inhibits JAK3 | |
| 6290 | WZ 4002 |
| Potent mutant-selective EGFR inhibitor | |
Degraders |
|
| Cat. No. | Product Name / Activity |
| 7258 | Gefitinib-based PROTAC® 3 |
| Potent EGFR Degrader | |
| 7395 | MS 154 |
| Potent and selective cereblon-recruiting Degrader (PROTAC®) of mutant EGFR | |
| 7397 | MS 39 |
| Potent and selective VHL-recruiting Degrader (PROTAC®) of mutant EGFR | |
| 7261 | SJF 1521 |
| Selective EGFR Degrader | |
| 7262 | SJF 1528 |
| Potent EGFR Degrader; also degrades HER2 | |
Controls |
|
| Cat. No. | Product Name / Activity |
| 7396 | MS 154N |
| Negative control for MS 154 (Cat No. 7395) | |
| 7398 | MS 39N |
| Negative control for MS 39 (Cat. No. 7397) | |
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified: EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4).
EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/heterodimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, decreased apoptosis and increased cell proliferation.
External sources of pharmacological information for EGFR :
Literature for EGFR
Tocris offers the following scientific literature for EGFR to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Angiogenesis in Cancer Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
EGF Receptor Gene Data
| Gene | Species | Gene Symbol | Gene Accession No. | Protein Accession No. |
|---|---|---|---|---|
| EGFR | Human | EGFR | NM_005228 | P00533 |
| Mouse | Egfr | NM_207655 | Q01279 | |
| Rat | Egfr | NM_031507 | Q62954 | |
| ErbB2 | Human | ERBB2 | NM_001005862 | P04626 |
| Mouse | Erbb2 | NM_001003817 | P70424 | |
| Rat | Erbb2 | NM_017003 | P06494 | |
| ErbB3 | Human | ERBB3 | NM_001005915 | P21860 |
| Mouse | Erbb3 | NM_010153 | Q61526 | |
| Rat | Erbb3 | NM_017218 | Q62799 | |
| ErbB4 | Human | ERBB4 | NM_001042599 | Q15303 |
| Mouse | Erbb4 | NM_010154 | Q61527 | |
| Rat | Erbb4 | NM_021687 | Q62956 |
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyRequest PDFTaken from the Cancer Product Guide Edition 3
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDF